menu toggle
Português Español 中文 한국어 日本語 Français Pу́сский Deutsch English

Q&A – How the tendency towards decentralized supply chains has changed in CGT

By Jennifer Fenwick

Jennifer Fenwick, Senior Manager, Personalized Supply Chain, joins Dr Matthew Lakelin, Vice President, Scientific Affairs and Product Development at TrakCel, for a Q&A about decentralized supply chains.
Decentralized clinical trials for CGTs
They delve into the reasons why therapy developers should consider investing in an integrated, digital supply chain for CGT, and why finding the right partners will be critical to their digital infrastructure success. 

Contact us

Connect with with our cell and gene therapy experts today. We look forward to hearing from you. 
Topics:
Cell and gene therapy Commercialization

About The Author

JenniferF
Jennifer Fenwick
Senior Manager, Personalized Supply Chain
World Courier
View Bio

Related Content

Manufacturers

Essential guide to cell and gene therapy (CGT)  commercialization

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2024
Rainbow-Abstract

Manufacturers

ICS: Logistics decisions impacting new cell and gene therapies

Inverted color AmerisourceBergen icon
ICS Connect
July 2017
Logistics decisions impact new cell & gene therapies

Manufacturers

Three Ways Title Model Powers Pharma Innovation

Inverted color AmerisourceBergen icon
ICS Connect
May 2017
016_Site_Thumb